Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 plus irinotecan as second-line therapy for advanced cholangiocarcinoma and gallbladder carcinoma
2018-002936-26Phase 2Completed
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and irinotecan in cholangiocarcinoma (CCA), gallbladder cancer and biliary cancer, sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Median progression-free survival. Started Dec 2018; status: completed.
02
Drugs
trifluridine + tipiracilirinotecan
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancerbiliary cancer
Beyond the preview
Go deeper on 2018-002936-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002936-26.